论文部分内容阅读
目的：观察尼莫地平注射液防治蛛网膜下腔出血（ＳＡＨ）后迟发性脑血管痉挛（ＤＣＶＳ）的疗效。方法：将６０例ＳＡＨ病人随机分为尼莫地平组（男性２０例，女性１０例，年龄５４±ｓ６ａ）和对照组（男性２１例，女性９例，年龄５５±５ａ）各３０例。２组均于发病７２ｈ内接受治疗，对照组用脱水、止血等常规疗法，尼莫地平组在常规疗法基础上加用尼莫地平注射液５０ｍＬ（含１０ｍｇ），静脉滴注，ｑｄ×１４ｄ。结果：尼莫地平组ＤＣＶＳ发生率和ＳＡＨ死亡率明显低于对照组（Ｐ＜０．０５）；再出血发生率２组无明显差异（Ｐ＞０．０５）。结论：尼莫地平注射液预防ＳＡＨ后ＤＣＶＳ疗效确切，且无增加再出血的危险。
Objective: To observe the effect of nimodipine injection on prevention of delayed cerebral vasospasm (DCVS) after subarachnoid hemorrhage (SAH). Methods: Sixty SAH patients were randomly divided into nimodipine group (20 males, 10 females, age 54 ± s6a) and control group (21 males and 9 females, age 55 ± 5a). The two groups were treated within 72 hours after the onset of disease. The control group was treated with conventional therapy such as dehydration and hemostasis. The nimodipine group was given nimodipine 50 ml (including 10 mg) on the basis of conventional therapy and intravenously dripped qd for 14 days. Results: The incidence of DCVS and SAH mortality in nimodipine group were significantly lower than those in control group (P <0.05). There was no significant difference in the incidence of rebleeding between the two groups (P> 0.05). CONCLUSION: Nimodipine injection is effective in preventing DCVS after SAH without any risk of rebleeding.